Mobility schemes in the Fields of Pharmaceutical and Medical Biotechnologies Marie Curie Actions ENEA, 20 June 2012 Alessandra Luchetti Head of Unit, DG EAC.C3
Outline 1. MCAs in FP7 2. MCAs achievements 3. MCAs in Pharmaceutical & Medical Biotechnologies 4. Commission proposal for Marie Skłodowska-Curie Actions in Horizon 2020
Basics Marie Curie Actions EU fellowships programmes since 1990 Marie Curie label since 1996 Training, mobility and career development Implemented through the People Programme (2007-2013) Pierre and Marie Curie honeymoon, 1895
Key features Bottom-up approach Mobility, both transnational and intersectoral Main EU programme providing structured doctoral training, including industrial doctorates Opening research careers at European and international level Enhanced business-academia collaboration and staff exchange Excellent employment and working conditions, in line with the EU Charter and Code for Researchers
MCAs & EU2020 Strategy Europe 2020 Flagship Initiatives Innovation Union Youth On the Move Agenda for New Skills and Jobs 1 million more researchers Attract and train young people to become researchers Improve quality of doctoral training Involve businesses in doctoral training Promote researchers mobility across sectors, countries and disciplines Attractiveness of European universities Stronger links between education, research and innovation Equip researchers with relevant skills that will match both public and private sector needs Improve career prospects of doctoral candidates
Funds Where does the money come from? The 7th Framework Programme for research and technological development (FP7) Collaborative research (10 thematic areas) Cooperation M 32 413 Frontier Research Ideas M 7510 Marie Curie Actions Research Capacity Total FP7 budget 2007 2013 = M 50 521 JRC M 1751 Euratom M 2751 (Nuclear research) Capacities M 4097 People M 4 750
8 Actions Marie Curie Action Objective Initial training of researchers (1900 M ) Life-long training and career development (1170 1400 M ) Initial Training Networks (ITN) Intra-European Fellowships (IEF) Career Integration Grants (CIG) Co-funding of regional, national, international programmes (COFUND) Improve career perspectives of early stage researchers (ESR) in both public & private sector Career development of experienced researchers (ER) (e.g. diversification of skills/competencies; integrate a stable position after mobility) Industry dimension (250-450 M ) International dimension World fellowships (1170 1400 M ) Industry-Academia Partnerships and Pathways (IAPP) International Outgoing Fellowships (IOF) International Incoming Fellowships (IIF) International Research Staff Exchange Scheme (IRSES) Open and foster dynamic pathways between public research organisations and private research commercial enterprises Reinforce the extra-european dimension of the European Research Area (ERA) through mobility, training, knowledge transfer and cooperation
Profile of recruited researchers Applicants Who can apply to what? Individual researchers Research Organisations Research funding bodies Senior Post-docs (MER*) > 10 years Post-docs (ER*) > 4 years or PhD IEF IOF IIF CIG IAPP IRSES COFUND Post-graduates (ESR*) ITN < 4 years + no PhD *ESR: Early Stage Researcher / ER: Experienced Researchers / MER: More Experienced Researcher
FP7 Achievements 1996-2010 50 000 Marie Curie Researchers 35000 30000 25000 20000 15000 10000 5000 0 1996-1998 1999-2002 2002-2006 2007-2010 2011-2013 COFUND 8% Economics 2% Mathematics 3% Social Sciences and Humanities 8% Chemistry 10% Life Sciences 28% Environmental and Geo-sciences 11% Physics 12% Budget distribution by scientific panel in FP7 (bottom up approach) Information Science and Engineering 18% 2007-2011: EU contribution spent: ~ 2,5 billion Funded research projects : > 6 500 Supported PhD: >10 000 Women participation rate: 38% (close to 40% target) SMEs play a major role: > 50% of all businesses participating in IAPP and ITN 50-60% of the budget dedicated to research on societal challenges
FP7 Achievements FP7 Marie Curie researchers coming from all over the world (around 130 nationalities)
FP7 Achievements FP7 Marie Curie host organisations in > 80 countries 10 MAIN DESTINATIONS
Pharmaceutical & Medical Biotechnologies in FP7 MCA Out of all 512 projects on health (including public health): 460 referred to drugs, pharma or medical biotech in their title or abstract These 460 projects were awarded a total EU contribution of 207.4 million
An example: IAPP (1) IAPP 2008: NANOPORATION (230674) ULTRASONIC PORATION OF DRUG NANOCAPSULES Start date: 1 st May 2009 Coordinator: University of Dundee, UK Institute for Medical Science and Technology Partners: InsighTec Ltd, Israel Manufacturer/developer therapeutic ultrasound equipment CapsuTech Ltd, Israel Producer/developer of drug delivery nanocapsules systems EU Contribution: 2,1M (281 fellow-months) Involved Fellows: - 15 seconded staff (4 ESR, 6 ER, 5 MER) (of whom 4 women) for a total of 161 months - 5 recruitments (of whom 4 women) for 24 months each 23 May 2012
An example: IAPP (2) MRI instrument Objective: Ultrasound-focused technology Main Tasks of the consortium: To explore specific solutions to overcome the current challenges of drug delivery to cancer cells using MRI (magnetic resonance imaging) guided focused ultrasound 1. Develop nano-capsules based drug carrier systems (CAP); 2. Optimise protocols for releasing active drugs (DUNDEE); 3. Develop more precise and efficient MRIguided tumors cell populations targeting (INS). Targeted drug delivery
2012 Calls for Proposals ITN 20/07/2011-12/01/2012 M 423 IRSES 20/07/2011-18/01/2012 M 30 COFUND 19/10/2011-15/02/2012 M 110 CIG 20/10/2011-06/03 + 18/09/2012 M 40 IAPP 19/10/2011-19/04/2012 M 80 IEF 13/03/2011-16/08/2012 M 120 IOF 13/03/2011-16/08/2012 M 35 IIF 13/03/2011-16/08/2012 M 45 Calls for proposals: http://ec.europa.eu/research/participants/portal/ Current MCA vacancies for researchers on the EURAXESS mobility portal: http://ec.europa.eu/euraxess/index_en.cfm
HORIZON 2020
Horizon 2020 Excellent Science - Priority I European Research Council Future and Emerging Technologies Marie Skłodowska-Curie Actions Research Infrastructures Industrial leadership - Priority II Leadership in enabling and industrial technologies Access to risk finance Innovation in SMEs Societal challenges - Priority III Health, demographic change and wellbeing Food security, sustainable agriculture, marine and maritime research, bio-economy Secure, clean and efficient energy Smart, green and integrated transport Climate action, resource efficiency and raw materials Inclusive, innovative and secure societies EIT JRC non-nuclear action
MCAs Objective & Rationale Main objective Ensure the optimum development and dynamic use of Europe s intellectual capital in order to generate new skills and innovation Rationale Encourage new, creative and innovative types of training Identify excellent talents in research and innovation in international competition Make best researchers in Europe and the world work together across countries, sectors and disciplines Create a whole new mind-set in Europe, crucial for creativity and innovation Marie Curie Actions = excellent researchers training + mobility for career development
MCSAs in H2020 Marie Skłodowska-Curie Actions under Horizon 2020 Proposed Budget (2014-2020): 5.75 billion 1. Fostering new skills through excellent initial training of researchers 2. Nurturing excellence through cross-border and cross-sector mobility 3. Stimulating innovation through cross-fertilisation of knowledge 4. Increasing structural impact by co-funding the activities 5. Specific support and policy action
MCAs vs MCSAs ITN (including EID and IDP) Action 1 Early-stage Researchers Doctoral and initial training of researchers proposed by international networks of organisations from public and private sectors IEF IOF IIF CIG Action 2 Experienced Researchers Individual fellowships for most promising experienced researchers to develop their skills through international or inter-sector mobility IAPP IRSES Action 3 Exchange of Staff International and inter-sector cooperation through the exchange of research and innovation staff COFUND Action 4 COFUND Co-funding of regional, national and international programmes covering actions 1 and 2
Key Features Bottom-up approach remains Fostering key skills and competences for research and innovation Main EU programme providing structured doctoral training, including industrial doctorates Mobility, both trans-national and inter-sectoral Opening research careers at European and international level Enhanced business-academia collaboration and staff exchange Excellent employment and working conditions, in line with the EU Charter and Code for Researchers Role model with pronounced structuring effect on regional, national and other international programmes
Key Features Cross-cutting issues Gender balance Strengthening the participation of SMEs Synergies with the societal challenges and the industrial technologies Broad participation of businesses and other socio-economic actors Increased possibility of the portability of grants Stronger emphasis on communicating results and on outreach activities Extended use of the scale of unit costs (including indirect costs)
H2020 Expected Impact 2014-2020 ~ 65.000 researchers to be supported, including 25.000 doctoral candidates ~ 200.000 scientific publications in high impact peer-reviewed journals ~ 1.500 patent applications ~ 100 spin-offs created ~ 350-400 new regional / national / international programmes to be created targeting international and intersectoral training, and career development of research and innovation staff
Marie Curie Actions Website http://ec.europa.eu/mariecurieactions Horizon 2020 http://ec.europa.eu/research/horizon2020
Thank you for your attention alessandra.luchetti@ec.europa.eu